These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20660601)

  • 1. Triethylenetetramine pharmacology and its clinical applications.
    Lu J
    Mol Cancer Ther; 2010 Sep; 9(9):2458-67. PubMed ID: 20660601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.
    Cooper GJ
    Drugs; 2011 Jul; 71(10):1281-320. PubMed ID: 21770477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
    Hyvönen MT; Weisell J; Khomutov AR; Alhonen L; Vepsäläinen J; Keinänen TA
    Drug Metab Dispos; 2013 Jan; 41(1):30-2. PubMed ID: 23024204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triethylenetetramine and metabolites: levels in relation to copper and zinc excretion in urine of healthy volunteers and type 2 diabetic patients.
    Lu J; Chan YK; Gamble GD; Poppitt SD; Othman AA; Cooper GJ
    Drug Metab Dispos; 2007 Feb; 35(2):221-7. PubMed ID: 17108057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fate of orally administered triethylenetetramine dihydrochloride: a therapeutic drug for Wilson's disease.
    Kodama H; Meguro Y; Tsunakawa A; Nakazato Y; Abe T; Murakita H
    Tohoku J Exp Med; 1993 Jan; 169(1):59-66. PubMed ID: 8211970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complex formation equilibria of Cu(II) and Zn(II) with triethylenetetramine and its mono- and di-acetyl metabolites.
    Nurchi VM; Crisponi G; Crespo-Alonso M; Lachowicz JI; Szewczuk Z; Cooper GJ
    Dalton Trans; 2013 May; 42(17):6161-70. PubMed ID: 23202417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of cardiovascular autonomic dysfunction following anti-copper therapy in Wilson's disease.
    Deguchi K; Sasaki I; Touge T; Tsukaguchi M; Ikeda K; Shimamura M; Urai Y; Watanabe S; Takeuchi H; Kuriyama S
    J Neurol; 2005 Apr; 252(4):495-7. PubMed ID: 15726258
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics, pharmacodynamics, and metabolism of triethylenetetramine in healthy human participants: an open-label trial.
    Lu J; Poppitt SD; Othman AA; Sunderland T; Ruggiero K; Willett MS; Diamond LE; Garcia WD; Roesch BG; Cooper GJ
    J Clin Pharmacol; 2010 Jun; 50(6):647-58. PubMed ID: 20145262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Disposition behavior and absorption mechanism of trientine, an orphan drug for Wilson's disease].
    Tanabe R
    Hokkaido Igaku Zasshi; 1996 Mar; 71(2):217-28. PubMed ID: 8641677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triethylenetetramine (trientine): a caloric restriction mimetic with a new mode of action.
    Pietrocola F; Castoldi F; Madeo F; Kroemer G
    Autophagy; 2020 Aug; 16(8):1534-1536. PubMed ID: 32544364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triethylenetetramine modulates polyamine and energy metabolism and inhibits cancer cell proliferation.
    Hyvönen MT; Ucal S; Pasanen M; Peräniemi S; Weisell J; Khomutov M; Khomutov AR; Vepsäläinen J; Alhonen L; Keinänen TA
    Biochem J; 2016 May; 473(10):1433-41. PubMed ID: 27001865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex N-acetylation of triethylenetetramine.
    Cerrada-Gimenez M; Weisell J; Hyvönen MT; Park MH; Alhonen L; Vepsäläinen J; Keinänen TA
    Drug Metab Dispos; 2011 Dec; 39(12):2242-9. PubMed ID: 21878558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wilson's disease with cognitive impairment and without extrapyramidal signs: improvement of neuropsychological performance and reduction of MRI abnormalities with trientine treatment.
    Chung EJ; Kim EG; Kim SJ; Ji KH; Seo JH
    Neurocase; 2016; 22(1):40-4. PubMed ID: 25988284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triethylenetetramine (TETA).
    ; ;
    Toxicol Ind Health; 2023 Apr; 39(4):183-187. PubMed ID: 36941775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copper(II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments.
    Lu J; Gong D; Choong SY; Xu H; Chan YK; Chen X; Fitzpatrick S; Glyn-Jones S; Zhang S; Nakamura T; Ruggiero K; Obolonkin V; Poppitt SD; Phillips AR; Cooper GJ
    Diabetologia; 2010 Jun; 53(6):1217-26. PubMed ID: 20221822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pregnancy in a patient treated with trientine dihydrochloride for Wilson's disease].
    Desbriere R; Roquelaure B; Sarles J; Boubli L
    Presse Med; 1998 May 2-9; 27(17):806. PubMed ID: 9767885
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine).
    Dahlman T; Hartvig P; Löfholm M; Nordlinder H; Lööf L; Westermark K
    QJM; 1995 Sep; 88(9):609-16. PubMed ID: 7583074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chelating polymeric beads as potential therapeutics for Wilson's disease.
    Mattová J; Poučková P; Kučka J; Skodová M; Vetrík M; Stěpánek P; Urbánek P; Petřík M; Nový Z; Hrubý M
    Eur J Pharm Sci; 2014 Oct; 62():1-7. PubMed ID: 24815561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical recommendations and new therapies for Wilson's disease.
    Brewer GJ
    Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Wilson's disease: what are the relative roles of penicillamine, trientine, and zinc supplementation?
    Schilsky ML
    Curr Gastroenterol Rep; 2001 Feb; 3(1):54-9. PubMed ID: 11177695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.